top of page
frenelle hero web.jpg

Better is always possible.

Our Mission

At Frenelle Pharma we adapt and create. We think big about the small. We challenge ourselves to improve what already exists, and we refuse to accept “good enough”.

dog hero homepage.jpg
dog hero homepage.jpg

Our Mission

At Frenelle Pharma we adapt and create. We think big about the small. We challenge ourselves to improve what already exists, and we refuse to accept “good enough”.

About

Frenelle Pharma has invested decades in perfecting its innovative long-acting injectable (LAI) drug delivery technology, Faros™,  and we are poised to both disrupt markets and impact patients’ lives. We are using our Faros™ technology to deliver powerful solutions across multiple therapeutic areas.

doctor hero.jpg
doctor hero.jpg

About

Frenelle Pharma has invested decades in perfecting its innovative long-acting injectable (LAI) drug delivery technology, Faros™,  and we are poised to both disrupt markets and impact patients’ lives. We are using our Faros™ technology to deliver powerful solutions across multiple therapeutic areas.

background (15).jpg

Frenelle Pharma has successfully launched three companies built on our Faros™
technology, each focused on a therapeutic area: SpineThera, a Phase 2 therapeutic
company advancing SX600 for the potential to transform treatment of lumbar radicular
pain (sciatica); Frenelle PBC, a collaboration with the Mayo Clinic to develop long-acting
injectables for substance use disorders with a mission to maximize access and
utilization; and Anumio, an animal health company focused long-acting injectable drugs for companion animals approvable via the FDA’s Expanded Conditional Approval
pathway to rapidly advance to commercialization.

Anumio

Stage 1

Stage 2

Stage 3

Stage 4

Frenelle PBC

SpineThera

Untitled(1)awdawd_edited.jpg
Untitled(1)awdawd_edited.jpg
Untitled(1)awdawd_edited.jpg

The Frenelle Pharma systematic approach drives success from discovery to commercialization:

Stage 1  - Identification and selection of new opportunities
Stage 2 - Pre-clinical evaluation to demonstrate key product performance attributes

Stage 3 – Proof of concept clinical trial to determine a go/no-go decision

Stage 4 – Pivotal studies to enable regulatory approval and product launch

We welcome inquiries about direct investment in our subsidiaries as well as co-
development and out-licensing opportunities for the Faros™ technology.

Frenelle Pharma has successfully launched three companies built on our Faros™ technology, each focused on a therapeutic area: SpineThera, a Phase 2 therapeutic  company advancing SX600 for the potential to transform treatment of lumbar radicular  pain (sciatica); Frenelle PBC, a collaboration with the Mayo Clinic to develop long-acting injectables for substance use disorders with a mission to maximize access and utilization; and Anumio, an animal health company focused long-acting injectable drugs for companion animals approvable via the FDA’s Expanded Conditional Approval pathway to rapidly advance to commercialization.

Anumio

Stage 1

Stage 2

Stage 3

Stage 4

Frenelle PBC

SpineThera

Untitled(1)awdawd_edited.jpg
Untitled(1)awdawd_edited.jpg
Untitled(1)awdawd_edited.jpg

The Frenelle Pharma systematic approach drives success from discovery to commercialization:

Stage 1  - Identification and selection of new opportunities
Stage 2 - Pre-clinical evaluation to demonstrate key product performance attributes

Stage 3 – Proof of concept clinical trial to determine a go/no-go decision

Stage 4 – Pivotal studies to enable regulatory approval and product launch

We welcome inquiries about direct investment in our subsidiaries as well as co-
development and out-licensing opportunities for the Faros™ technology.

Frenelle Pharma has successfully launched three companies built on our Faros™ technology, each focused on a therapeutic area: SpineThera, a Phase 2 therapeutic company advancing SX600 for the potential to transform treatment of lumbar radicular pain (sciatica); Frenelle PBC, a collaboration with the Mayo Clinic to develop long-acting injectables for substance use disorders with a mission to maximize access and utilization; and Anumio, an animal health company focused on long-acting injectable drugs for companion animals approvable via the FDA’s Expanded Conditional Approval pathway to rapidly advance to commercialization.

Anumio

Frenelle PBC

SpineThera

Untitled(1)awdawd_edited.jpg
Untitled(1)awdawd_edited.jpg
Untitled(1)awdawd_edited.jpg

Stage 4

Stage 3

Stage 2

Stage 1

The Frenelle Pharma systematic approach drives success from discovery to commercialization:
 

Stage 1  - Identification and selection of new opportunities
Stage 2 - Pre-clinical evaluation to demonstrate key product performance attributes

Stage 3 – Proof of concept clinical trial to determine a go/no-go decision

Stage 4 – Pivotal studies to enable regulatory approval and product launch

We welcome inquiries about direct investment in our subsidiaries as well as co-development and out-licensing opportunities for the Faros™ technology.

Our Business Model

solution hero web.jpg

Our Technology

Frenelle’s innovative long-acting injectable (LAI) drug delivery technology, Faros™, has demonstrated traction across three disparate areas of high unmet need – back pain, substance use disorders, and animal health. The Faros™ technology has been proven in several animal models and a phase 2 clinical study. Looking beyond LAIs, the Frenelle team is exploring additional applications of the Faros platform, including inhalation.

perfect spheres.jpg

Our Technology

Frenelle’s innovative long-acting injectable (LAI) drug delivery technology, Faros™, has demonstrated traction across three disparate areas of high unmet need – back pain, substance use disorders, and animal health. The Faros™ technology has been proven in several animal models and a phase 2 clinical study. Looking beyond LAIs, the Frenelle team is exploring additional applications of the Faros platform, including inhalation.

solution hero web.jpg
perfect spheres.jpg

News and Events

January 10, 2025

Frenelle Pharma Officially Launches: CEO Missling Attends JPM 2025 Representing Frenelle’s Portfolio

yes lens fade.jpg
bottom of page